Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486577 | 0.86 | KDM4E (0.62) | PTGS1PTGS2RAB9ANPC1CYP1A2 | |
| SCHEMBL2392861 | 0.82 | RAB9A (0.50) | PTGS1PTGS2RAB9ANPC1CYP1A2 | |
| SCHEMBL20798098 | 0.81 | RAB9A (0.49) | PTGS1PTGS2RAB9ANPC1CYP1A2 | |
| SCHEMBL3486348 | 0.81 | MAP3K5 (0.63) | RAB9ANPC1MAPTKDM4EHPGD | |
| SCHEMBL3146263 | 0.79 | MAP3K5 (0.47) | — | |
| SCHEMBL17962528 | 0.78 | PTGS1 (0.50) | PTGS1PTGS2RAB9ANPC1CYP1A2 | |
| SCHEMBL9217808 | 0.77 | PTGS1 (0.52) | PTGS1PTGS2RAB9ANPC1CYP1A2 | |
| SCHEMBL9217814 | 0.77 | PTGS1 (0.52) | PTGS1PTGS2RAB9ANPC1CYP1A2 | |
| SCHEMBL3485678 | 0.76 | MAP3K5 (0.73) | RAB9ANPC1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL1495230 | 0.76 | RAB9A (0.53) | PTGS1PTGS2RAB9ANPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2808020-A1 | Beta-Amyloid Pet Imaging Agents | The Government Of The United States, As Represented by The Secretary Of Health And Human Services (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20140341812-A1 | BETA-AMYLOID PET IMAGING AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-11-20 | — | — | US | disclosed |
| EP-2021340-B1 | BETA-AMYLOID PET IMAGING AGENTS | US GOVERNMENT (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8703096-B2 | Beta-amyloid PET imaging agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-04-22 | — | — | US | disclosed |
| US-20110008255-A1 | BETA-AMYLOID PET IMAGING AGENTS | THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2009029375-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| EP-2021340-A2 | BETA-AMYLOID PET IMAGING AGENTS | The Government Of The United States, As Represented by The Secretary Of Health And Human Services (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007124345-A2 | BETA-AMYLOID PET IMAGING AGENTS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008255-A1 | BETA-AMYLOID PET IMAGING AGENTS | APP, BACE1, PSEN1 | PTGS1 3539/4885PTGS2 2977/4885RAB9A 3988/4885 |
| US-20140341812-A1 | BETA-AMYLOID PET IMAGING AGENTS | APP, BACE1, PSEN1 | PTGS1 3539/4885PTGS2 2977/4885RAB9A 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.